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The ability of scientists to identify genes believed to cause inherited diseases, 
including familial cancers, has become considerably refmed over the last two 
decades because of technological breakthroughs. When research published in 
199S appeared to show that genetic mutations linked to breast and ovarian 
cancers (BRCAI and BRCA2) occur more frequently in Jews of Eastern Euro-
pean descent than in the generat population, the first response among Jewish 
women was to rush to participate in research. When a gene linked to colorectal 
cancer was identified in 6% of the Jewish population in 1997, however, press 
reports began to carry inaccurate and inflammatory headlines about Jewish 
'mutant gene carriers', raising fears of discrimination and loss of privacy. 
Some rabbis and other leaders of the Jewish community began to quietly 
advise Jews not to get a genetic test or participate in genetics research until 
legal protections against discrimination are established. At the present time, a 
subtle tension is developing between the Jewish tradition of encouraging the 
acquisition of knowledge, particularly medical knowledge (exemplified by the 
community's successful collaboration with genetic researchers when tests for 
Tay-Sachs disease were developed in the 1970s) and the fear of potential dis-
crimination or stigmatization. In order to address this tension, and ensure the 
continued participation by the Jewish community in critical genetics research, 
a framework based on the mutual interests of researchers and participants 
should be formulated. Such a framework of dialogue and policy would be use-
ful in building an important element of trust for the Jewish community and 
other distinct communities who are sought for such research. 
No social group is better equipped either in its ability 
to provide reliable, ordered health data or in its caPacity 
to interpret its genetic and medical implications than the 
Jewish community. At the same time, no group has great-
er reason to be wary of the way in which such implications 
can be misused [1]. 
The explosion of knowledge in the science of genetics 
over the decade has profoundly affected the ability to 
diagnose inherited disease and encouraged bold theories 
of genetic therapy. Since 1990, the United States govern-
ment has ftrmly endorsed the international 15-year effort 
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and sequence all of the human genes. (The Human 
Genome Project is under the auspices of the Department 
of Energy's Human Genome Program and the National 
Institutes of Health's National Human Genome Research 
Institute). This ambitious effort will further expand scien-
tific understanding as well as the possibility of identifying 
genetic mutations and implementing medical interven-
tion on a germline level [2]. Once the province of specialty 
journals, reports on new findings in genetics have filtered 
down to the popular press and headlines announcing that 
'the' gene for some condition or other has been 'discov-
ered' are weekly occurrences. 
This was the case in 1995, when genetic mutations 
associated with some forms of breast and ovarian cancer, 
BRCA 1 and BRCA2, were identified by researchers. The 
studies suggested that these genetic alterations occurred 
with higher frequency in Jewish women of Eastern Euro-
pean ancestry (Ashkenazi Jews) than in those of other eth· 
nic groups [ 3, 4]. Widely covered by the media, these find-
ings which linked an individual's genetic make-up, pro-
pensity for disease, and ethnic heritage set off a chain 
reaction within the organized Jewish community because 
of both the benefits and the possible consequences created 
by such discoveries. 
When the news that the mutations had been identified 
appeared in the popular press, the reaction of the orga-
nized Jewish community was predictable: to a people for 
whom learning is an article of faith, knowledge means 
power. Although there was certainly a component of fear 
regarding the news of an intensified vulnerability to can-
cer, many Jewish women with family histories ofbreast or 
ovarian cancer wanted to know if they carried these genet-
ic mutations- they wanted to have access to a genetic test. 
The discovery of the mutation implied only that Ashkena-
zi Jewish women had a distinct and potentially heightened 
hereditary susceptibility to certain forms of breast and 
ovarian cancers. For example, it is estimated that no more 
than 10% of breast cancer is caused by hereditary genetic 
mutations [5]. Even though these women understood that 
such a test could not possibly be 100% predictive of the 
onset ofbreast or ovarian cancer, they just wanted to have 
as much information as they could get their hands on. 
Some Jewish community leaders and researchers even 
discussed the possibility of population-based screening 
[6, 7]. 
Jewish women throughout the country also wanted to 
help researchers better understand this issue. By early 
1996, for example, over 5,000 Ashkenazi Jewish women 
and men had volunteered to participate in an NIH-spon· 
sored project in the metropolitan Washington, D.C. area 
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[8]. NIH researchers, in fact, did seek the active endorse-
ment and assistance from Jewish community organiza-
tions and leadership to actively promote participation in 
the study. 
This active enthusiasm was not uniform throughout 
the United States. Concerned breast cancer advocates and 
some Jewish leaders in the Boston community were 
actually dissuading Jewish women from getting a genetic 
test or participating in a genetics research study sponsored 
by the Dana Farber Cancer Institute. The researchers had 
asked the Jewish leaders if they would be interested in 
helping involve the local community in further cancer 
genetics research and proposed a theoretical study. Those 
leaders expressed concern about the lack of adequate pub-
lic policy protections against genetic discrimination, and 
politely declined on behalf of the community [9, 1 0]. 
Then in 1997, when members of a research team at 
Johns Hopkins found a genetic mutation for colorectal 
cancer that they predicted was present in 6% of the Jewish 
community, a new anxiety arose. Hadassah, the country's 
largest Jewish women's organization with a history for 
advocating for women's health issues, began getting 
phone calls from concerned members of the Jewish com-
munity. The questions ranged from: 'Do Jews really have 
more genetic mutations than other people? to 'Why are 
Jews being studied so extensively?' Other leaders of 
Jewish organizations also began to acknowledge the deep-
ening community concerns [ 11-13]. 
Rabbi Moshe Tendler, a renowned medical ethicist at 
Yeshiva University and a highly influential and visible 
Orthodox leader, was then described in The New York 
Times as saying that he would discourage Jews from parti-
cipating in research until protections are passed. Rabbi 
Tendler stated: 'There's so much promise that I always 
walk gingerly when it means holding back any aspect of 
research. Yet, you have to weigh the risks against the ben-
efits' [10]. 
This concern regarding discrimination in obtaining 
insurance or in the job market is a powerful disincentive 
for participation in testing programs and research. In 
addition to anecdotal reports of discrimination, two aca-
demic studies also claim to have documented genetic dis-
crimination [14, 15]. Fears of such discrimination have 
led some individuals to avoid testing even where it might 
have been medically useful [16]. In early May 1998,Asso-
ciated Press cited an NIH study in which 32% of women 
who were asked to participate in breast cancer genetic 
mutations research actually declined. Most of these wom-
en cited fear of discrimination and a loss of privacy as 
their reasons for not participating in the research [17]. 
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Both the Jewish community and the genetics research 
establishment have been critical voices calling for the pas-
sage of federal genetic nondiscrimination legislation. 
The community leaders, as well as the individual wom-
en who called Hadassah, feared genetic discrimination on 
a number of levels. If women either got a genetic test or 
participated in a research study, there was no sure way to 
protect them against insurance or employment discrimi-
nation based on genetic information. They voiced con-
cern that Ashkenazi Jewish women could become part of 
an 'insurance underclass', unable to obtain or afford prop-
er health insurance. The Jewish community had learned 
of the well-documented experiences of discrimination 
with respect to sickle cell anemia and other genetically 
linked diseases [ 18]. 
If individual members of the Jewish community were 
feeling vulnerable to potential discrimination as an unin-
tended result of the fast-breaking genetics research, mis-
leading media headlines and sound bites began to illumi-
nate the potential for group stigmatization as well. Head-
lines appeared in the Jewish and secular popular press 
announcing sentiments like 'Breast Cancer Strikes Jewish 
Women More Often Than Others' (which is patently 
false) and 'Ashkenazi Jews Weather News of Another 
Gene Flaw'. One magazine even went so far as to headline 
the 'Jewish gene' for breast and ovarian cancer, when 
referring to the BRCA1 mutation on its front cover [19-
21 ]. Immediately following the colorectal cancer an-
nouncement, a newspaper's headline attached to an opin-
ion article written by Hadassah to promote genetic anti-
discrimination legislation read, 'Protect Insurance for 
Mutant Gene Carriers [22]'. Such inflammatory language 
and reporting, both in the Jewish and secular press, con-
tributed to growing wariness and fears. In fact, it was 
reported that in a study of 20 Jewish families, opinions 
about breast cancer research varied: half supported it 
while the other half felt victimized by it [10]. 
Signs of the potential for group stigmatization also 
appeared on the Internet. An ominous example is found 
in a legislative 'Action Alert' and article published by 
B'nai B'rith, a large Jewish organization. As originally 
written, the alert and article mentioned the genetic predis-
position to breast cancer among Ashkenazi Jewish women 
and spoke of increased funding for breast cancer research. 
It called for passage of genetic nondiscrimination legisla-
tion. However, once it was posted on the Internet, it was 
hijacked by a 'white power' group and altered to read, 
'Jews get a special type of breast cancer caused by genet-
ics!' [23]. Needless to say, anti-Semites believed they had 
'substantiation' for their racist views about the 'genetic 
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inferiority' of Jews long before the onset of modem genet-
ic research. The fmdings simply provided additional but-
tressing for their argumentation that Jews are a racial 
group, and so necessarily have 'intelligence, behavioral 
and other differences built into their biology' [24]. 
The mere hint of notions of genetic inferiority raises 
historical sensitivity in the Jewish community. During the 
early 1900s, eugenicists played an influential role in the 
enactment of US laws restricting immigration of those felt 
to be genetically undesirable, especially Russian and Pol-
ish Jews and Southern Italians [25]. It goes without saying 
that the mention of 'Jewish genes' is chilling for many 
Jews, calling to mind the horrors of the Nazis' efforts to 
justify their 'Final Solution' as a remedy for the problem 
of Jews polluting the world with their 'inferior' genes. 
These concerns are at odds with the fact that the Jewish 
population generally recognizes the value of genetic re-
search. They see not only a potential medical benefit to 
their people, but also a way to contribute to society as a 
whole. This strong belief in social justice is a fundamental 
Jewish value. In urging Jews to participate in the 1996 
NIH study on BRCAl, Rabbi Matthew Simon, the presi-
dent of the United Jewish Appeal Federation of Greater 
Washington said: 'In history, Jews have bled for negative 
reasons', and characterized this study as an opportunity 
for Jews to give blood to help their people [26]. Citing the 
important health benefits that could be realized from such 
research, Dr. Kenneth Offit, a cancer genetics expert said: 
'I try telling people in the Jewish community that this 
gene research shouldn't be viewed as a stigma but as a real 
opportunity to provide a major breakthrough in under-
standing cancer' [27]. 
As an answer to the concern that Jews are 'targeted' by 
researchers, there clearly are sound scientific and other 
reasons why the Jewish community is studied often and 
early including: 
- the so-called 'founder effect' - when a population 
group is descended from a small handful of ancestors, 
and historically shuns intermarriage or is forcibly ghet-
toized, genetic lineages (including disease-causing mu-
tations) are maintained [28]; 
- the theory of 'genetic drift' or 'bottleneck' which occurs 
when a genetic mutation becomes common because 
the population in which it is found dwindles due to 
famine, war, epidemic, or other event, as happened to 
the Eastern European Jewish population in the 15th 
and 16th centuries [29], and 
- the willingness of the Jewish community to participate 
in medical studies as part of our religious mandate to 
do 'social justice' work [10]. 
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Although some of these factors might lead to the belief 
that Eastern European Jews are more likely than other 
groups to have genetic mutations, as Dr. Francis Collins 
of the National Human Genome Research Institute has 
said repeatedly, everyone - regardless of race, ethnicity or 
gender - has a handful of genetic mutations that confer 
some kind of negative trait or disease. As one researcher 
put it: 'Ashkenazi Jews aren't victims of their genes. It's 
just that we've learned about them first [30]'. Continuing 
to use the Jewish community as a starting point, r~ 
searchers are carrying on their work to discover genetic 
links to diseases and traits on every piece of human DNA. 
Unfortunately, the evolving nature of genetic discovery 
runs the risk of labelling Jews as possessing greater 'pro-
pensity' for genetic disease than members of other groups, 
and therefore may confer upon them early social harm. 
The Jewish community has considerable past history 
with addressing genetic disease. More than 30 years ago, 
Tay-Sachs, a devastating disorder causing progressive d~ 
terioration and death in very young children, was identi-
fied as an autosomal recessive trait common to members 
of the Ashkenazi Jewish community. Identification of this 
mutation led to a voluntary program, sponsored and pub-
licized by Jewish community organizations across the 
nation, for the testing of couples before pregnancy. As a 
result of this screening program and the integration of 
Tay-Sachs testing into prenatal care for Jewish women, 
there was a 90% reduction in the incidence of Tay-Sachs 
in the Jewish populations of the United States and Cana-
da from the period from 1970-1993 [31]. The Jewish 
community considers this success story an important 
legacy. 
Genetics research on predisposition to disease raises 
different challenges and a new paradigm from the Tay-
Sachs experience. The Tay-Sachs scenario was compelling 
because identification of the mutation gave the carriers, if 
not a cure, at least options and choices regarding produc-
ing a child with this totally disabling and fatal syndrome. 
That is not the case with BRCAl and BRCA2. Tay-Sachs 
can be diagnosed prenatally and manifests itself very early 
in life. The subjects of the current breast and ovarian can-
cer research have adult onset. Tay-Sachs is a recessive dis-
order which means the child who inherits a gene from 
each parent will definitely develop the disease, with its 
progressive deterioration until death within the first 
5 years oflife. However, if an individual is found to have a 
genetic mutation associated with cancer, for example, it is 
not known whether that individual will ever develop can-
cer and what the prognosis will be. If both prospective 
parents carry the Tay-Sachs trait or a fetus tests positive 
The Jewish Community in Genetics 
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for Tay-Sachs, there are choices regarding marriage, child-
bearing or termination. If individuals are told that they 
carry a defective gene that might make them more likely 
to develop cancer, they are faced with great uncertainty 
about the meaning of both the information and their alter-
natives. Predisposition to disease is not a diagnosis. 
There is another legacy to the successful experience 
with Tay-Sachs testing. Although Jews may not have more 
genetic mutations than other groups of people, they may 
be easier to study because a large collection of Tay-Sachs 
samples have been archived since the 1970s for future 
use. This readily available supply of tissue samples, iden-
tified by ethnic group (Ashkenazi Jews), is considered by 
researchers to be both convenient and efficient [32]. 
When it was reported that one of the colorectal cancer 
researchers relied on hundreds of samples from anony-
mous Jews who had been screened during the mass Tay-
Sachs testing of the early 1970s, without Institutional 
Review Board approval, some Jewish community mem-
bers admitted real concern [33, 34]. They learned that 
there exist no uniform guidelines that require Institution-
al Review Board approval for the use of anonymized 
stored tissue samples in research. Moreover, no regula-
tions require any consultation with the group or commu-
nity to be studied, when the stored tissue samples sought, 
though anonymized for individual identification, may be 
linked back to an identified group. 
How then can our approach to regulation of research 
risk adequately address these growing concerns raised by 
genetics research? Should we infer, for example, that all 
individuals who consented to Tay-Sachs testing in a clini-
cal context many years ago would have agreed to provide 
their tissue for whatever study a researcher may propose 
to conduct today? Perhaps individuals would be comfort-
able with the use of their tissue for cancer research, but 
uncomfortable with its use for support of behavioral 
genetic studies. Obviously, it is not possible to obtain con-
sent from all of these individuals. But should there be no 
process in which the relative risks and benefits of a genet-
ics research study on an ethnic group be evaluated before 
it proceeds using its stored tissue samples? Should there 
be a formal role for the community to advise or consult on 
future genetics of stored tissue samples? How might we 
define the community or its interests? At what point is it 
appropriate to share a proposed research protocol with 
the community? How might the informed consent process 
address these concerns for identifying group risks? 
These questions are not unique to the Jewish commu-
nity but are also of concern to other communities. In fact, 
the National Bioethics Advisory Commission is currently 
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addressing these issues in the context of examining the use 
of archived tissue samples and informed consent in genet-
ic research [35]. In addition, scientific journals are begin-
ning to address the broader topic of'group rights' in genet-
ics research involving human subjects [36-38]. 
searchers, they urged that 'Genetics researchers and mem-
bers of the Jewish community should maintain an ongo-
ing dialogue so that each may be apprised of the other's 
concerns about genetics research involving Jews' [ 40]. 
Many of these issues pose considerable challenges both 
to the Jewish community and the research establishment. 
In Apri11998, Hadassah, the Jewish Council for Public 
Affairs, and the National Human Genome Research Insti-
tute convened a meeting in Washington which brought' 
together the top rabbis and leaders from nearly every reli-
gious movement and significant organization in the Je-
wish community. The goal of the meeting was to 'ensure 
the continued participation by the Ashkenazi Jewish com-
munity in critical genetics research within a framework 
where risks to the community are considered and mini-
mized' [39]. At the meeting, researchers and Jewish lead-
ers made a commitment to join together to heighten 
lobbying efforts for genetic nondiscrimination legislation, 
to create a 'standard lexicon' of nonstigmatizing language 
to be used in the reporting of research fmdings, and to 
continue a dialogue. In a statement released by the Ameri-
can Jewish Congress and several noted genetics re-
Indeed, this meeting represented an important fliSt 
step in the recognition of mutual interests and in the 
building of an important element of trust. That sense of 
trust, based on the notion that community concerns and 
needs are being heard within the context of specific 
research goals, will go far in helping to move the genetics 
research agenda forward. If we are to reach the promise of 
the Human Genome Project to alleviate much human suf-
fering in all communities, we must continue to work 
together in partnership toward a framework of mutualism 
that includes policy and dialogue. Without trust and 
mutual respect, the very future of genetics research is at 
risk. 
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